Insights

Rare disease clinical trials face significant challenges, and with small patient populations, leveraging innovative statistical methodologies that can enhance statistical power is crucial. The Net Treatment Benefit, estimated from the Generalized Pairwise Comparisons methodology, provides a promising solution by integrating multiple clinical outcomes into a single assessment, extracting more information from the data.

Randomized controlled clinical trials are considered the gold standard for understanding treatment safety and efficacy. Rare disease trials struggle to recruit enough participants to demonstrate efficacy, creating a barrier to research and approval. However, Bayesian statistics utilize existing evidence and expert opinion to quantify uncertainty and inform trial design, reducing necessary sample size. 

A healthy relationship between sites and sponsors is critical to the success of clinical trials, including efficient and effective management, adaptability, innovation, problem-solving, and feedback mechanisms on the parts of those involved on both sides. Clinical research associate (CRA) competencies are key to creating and nurturing this relationship under all circumstances.

Although relatively rare, clinical investigator inspections by the U.S. Food and Drug Administration (FDA) can have a significant business impact. Audits are conducted more frequently than regulatory inspections, which are […]